«Movement of cancer cells,
tumor cell detection to be studied.»
Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR - V7 protein expression test using Epic Sciences» non-EPCAM-based circulating
tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration - resistant prostate cancer.
Not exact matches
However,
tumor cells are smart and have developed ways to avoid immune
detection.
«This development has the potential to enable earlier
detection of solid
tumors through a simple blood draw by substantially improving our ability to detect very low quantities of circulating DNA derived from
tumor cells,» says corresponding author Hunter Underhill, M.D., Ph.D., who initiated the research while in the lab of senior author Jay Shendure, M.D., Ph.D., a professor in genome sciences at the University of Washington.
By increasing fluorescence in these
cells, we could substantially improve the success of fluorescence
detection and
tumor removal.»
«The
cells that escape
detection are the ones that, if not removed, are the most likely to result in treatment failing and a
tumor recurring.
However,
tumors are made up of a variety of different
cell types, and it has been unclear whether photodynamic
detection identifies all of them.
Adds Liu: «With metastatic cancers accounting for around 90 % of deaths from solid
tumors, the hope is that one day a device that can enable the analysis of single
tumor cells circulating in the blood could make a big difference in early diagnosis,
detection and monitoring of numerous types of cancer, without invasive biopsies.»
Because diseases such as cancer tend to evade
detection by T -
cells» receptors, allowing a
tumor to grow unchecked, scientists have long sought «intel» on this process as a means of developing therapies that target malignant
cells, but leave healthy
cells alone.
Tumor cells develop mechanisms to evade
detection by the immune system by expressing a protein called PD - L1.
Tumor cells often bedeck themselves with sialyl - Lewisx molecules, and the rogue
cells could be using them to escape
detection by the immune system, he adds.
The technique, described in Biomaterials, uses gold nanoparticles and Raman scattering, a technology previously developed by Qian and Nie for cancer
cell detection (2007 Nature Biotech paper, 2011 Cancer Research paper on circulating
tumor cells).
Methods for detecting
tumor cells and DNA circulating in bodily fluids are currently under intense investigation for early
detection and cancer diagnostics; however, no existing technology meets the high sensitivity and specificity requirements needed to attain these goals.
The most common germ
cell tumor is called a teratoma, which is often benign and usually found on the tailbone (sacrococcygeal), which is good for early
detection.
Background In our institute, the first research program on disseminated
tumor cells (DTC)
detection in the bone marrow of early breast cancer patients was initiated in the late 90's; with about a thousand patients included, we constituted one of the largest cohort ever reported and contributed to the landmark report that established bone marrow DTC as a level - of - evidence 1 prognostic factor in early breast cancer (Braun, N Engl J Med 2005).
At the same time, excess TGF - β can deactivate attacking T -
cells, allowing the
tumor to avoid
detection by the immune system.
We conducted a meta - analysis in nonmetastatic breast cancer patients treated by neoadjuvant chemotherapy (NCT) to assess the clinical validity of circulating
tumor cell (CTC)
detection as a prognostic marker.
We are developing methods to discover these changes in individuals,
tumors, and even single
cells, to promote early
detection and treatments
Bottom row shows confirmation of the presence or absence of HB1.F3 NSCs within
tumors by PCR
detection of a DNA amplicon (293 bp) of the v - myc transgene, a unique identifier of the HB1.F3
cell line.
Any type of prognosis for the effectiveness of treatment and the future of the disease depends upon different and varying criteria including a
tumor's resistance to treatment, the
cell type of the
tumor,
tumor stage and size, and how much the
tumor has progressed prior to
detection.